PF 07905428
Alternative Names: PF-07905428Latest Information Update: 16 Jan 2025
Price :
$50 *
At a glance
- Originator Pfizer
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acne vulgaris
Most Recent Events
- 22 Nov 2024 Phase-I clinical trials in Acne vulgaris in Canada (Topical) (NCT06671834)
- 11 Nov 2024 Preclinical trials in Acne vulgaris in USA (Topical) before November 2024